Study of Tirofiban Administration in Patients With Aspirin and or Clopidogrel Resistance

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

263 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-05-31

Study Completion Date

2011-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will evaluate whether adding tirofiban, administered at high bolus dose on top of aspirin and clopidogrel will lead to a lower rate of periprocedural myocardial infarction after percutaneous coronary intervention in elective patients presenting with aspirin and/or clopidogrel resistance.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety of High-dose Tirofiban During Coronary Angioplasty

NCT00566891

Coronary Artery Disease

COMPLETED PHASE4

Study on Tirofiban With Aspirin in the Treatment of Acute Penetrating Artery Territory Infarction

NCT05310968

Branch Atheromatous Disease

COMPLETED PHASE4

Tirofiban and Enoxaparin in High Risk Coronary Intervention

NCT00790387

Acute Coronary Syndrome

COMPLETED PHASE4

Synergy Between Stent and Drugs to Avoid Ischemic Recurrences After Percutaneous Coronary Intervention

NCT00611286

Coronary Artery Disease

COMPLETED PHASE4

Study on Safety and Effectiveness of Three Doses of Argatroban as Anticoagulant in Percutaneous Coronary Intervention (PCI)

NCT00508924

Coronary Artery Disease Angina, Unstable

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study will investigate the effect of treatment with a high bolus dosage of Tirofiban (in addition to Aspirin, Heparin and 300mg or 600mg clopidogrel) on the rate of periprocedural myocardial infarction compared to Aspirin, Heparin (or bivalirudin) and 300mg or 600mg clopidogrel alone in patients resistant to aspirin and/or to clopidogrel.

This is a randomized, double blind, placebo controlled (with bailout tirofiban as rescue) multicenter study. Enrollment will last between 12 and 36 months depending on the final number of participating centres. The minimum follow-up will be 30 days after the index procedure.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Angioplasty, Transluminal, Percutaneous Coronary

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Aspirin, clopidogrel, Unfractioned heparin or bivalirudin plus tirofiban infusion given at high bolus dose

Group Type EXPERIMENTAL

Tirofiban

Intervention Type DRUG

Tirofiban infusion given as high bolus dose plus standard 14-24 hour infusion

2

Aspirin, clopidogrel, Unfractioned heparin or bivalirudin plus placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Saline infusion will be administered for 14-24 hours

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tirofiban

Tirofiban infusion given as high bolus dose plus standard 14-24 hour infusion

Intervention Type DRUG

Placebo

Saline infusion will be administered for 14-24 hours

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Glycoprotein IIb/IIIa inhibitor Glycoprotein IIb/IIIa inhibitor

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. All Patients older than 18 years scheduled for coronary angiography and/or PCI will be enrolled. \[Patients should be CK-MB negative (to avoid CK washout with revascularization) and also cTnI/T negative whereas other high-risk features will not lead to patient exclusion.
2. All consecutive patients with stable or unstable troponin and CK-MB negative coronary artery disease showing aspirin and or clopidogrel resistance (ACR) will be enrolled. These include:

* Patients with clinical indication to undergo angiography for possible revascularisation.
* Patients with ACR in whom catheter-based coronary intervention is planned based on previous angiogram.

Exclusion Criteria

1. Patients who can not give informed consent or have a life expectancy of \< 1 year
2. Evolving or Ongoing myocardial infarction (MI) (Persistence of or developing Q wave or ST segment elevation at ECG with or without typical chest pain or typical rapid rise and fall CK-MB or new LBBB) or patients in whom the treating physician intends to use a Gp IIB/IIIa inhibitors.
3. Administration of any GP IIb/IIIa receptor antagonist, anticoagulation, or lytic therapy in the previous 30 days
4. Serum creatinine more than 2.5 mg/dl (221 micromol/L)
5. Ongoing bleeding or bleeding diathesis or contraindication for anticoagulation or increase bleeding risk or history of bleeding in the last 1 year
6. Previous stroke or TIA or any intracranial pathology in the last six months
7. Major surgery or trauma within the previous six weeks
8. Platelet count \< 100.000 per cubic mm or HCT ,33% or Hb \< 11 gm/dL
9. Subjects who received low-molecular-weight heparin within the 24 hours prior to randomization
10. Subjects with an allergy or intolerance to aspirin, heparin, clopidogrel, or tirofiban
11. Patients with severe hypertension (SBP \> 180 mm Hg or DBP \> 110 mm Hg) or in cardiogenic shock (SBP 80 mm Hg or below for \> 30 minutes) or requiring IABP

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No